<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04986826</url>
  </required_header>
  <id_info>
    <org_study_id>00023050</org_study_id>
    <nct_id>NCT04986826</nct_id>
  </id_info>
  <brief_title>Exercise Effect on Transthyretin Stability</brief_title>
  <official_title>Exercise Effect on Transthyretin Stability in Master Athletes and Patients With Transthyretin Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study to investigate if exercise predisposes to transthyretin instability.&#xD;
      The investigators will evaluate the effect of exercise on transthyretin biochemistry.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an investigator initiated observational study, designed to study the effect of&#xD;
      exercise on transthyretin stability in three main populations: Group 1: healthy master&#xD;
      athletes who are 60 years or older. Group 2: Genotype positive (G+) cardiac phenotype&#xD;
      negative (P-) patients with variant ATTR (i.e. carriers without evidence of disease). Group&#xD;
      3: Patients with ATTR CA who have not been on a stabilizer (tafamidis) within the last 14&#xD;
      days prior to enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in percent transthyretin stability assay</measure>
    <time_frame>Change from baseline to 72 hours post-exercise</time_frame>
    <description>Transthyretin stability will be measured and expressed as a percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma transthyretin level</measure>
    <time_frame>Change from baseline to 72 hours post-exercise</time_frame>
    <description>Plasma transthyretin level will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma transthyretin fragments</measure>
    <time_frame>Change from baseline to 72 hours post-exercise</time_frame>
    <description>Plasma transthyretin fragments will be measured</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Amyloidosis Transthyretin</condition>
  <condition>Athlete Heart</condition>
  <arm_group>
    <arm_group_label>Healthy master athletes</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype positive phenotype negative transthyretin amyloidosis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenotype positive transthyretin amyloidosis</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Master athletes without evidence of transthyretin amyloidosis. Genotype positive phenotype&#xD;
        negative transthyretin amyloidosis, and phenotype positive transthyretin amyloidosis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General inclusion criteria: patients should be able to exercise on a treadmill or a bike,&#xD;
        willing to consent to the study procedures and willing to return to site during the follow&#xD;
        up period of 72 hours for repeated blood and urine collection&#xD;
&#xD;
        Specific inclusion criteria:&#xD;
&#xD;
          -  Group 1: Subjects must be at least 60 years of age and meet the master athlete&#xD;
             definition of: athletes engaged in cycling ≥8 hours per week or running ≥6 hours per&#xD;
             week or triathlon training (combination of swimming, cycling, running) ≥8 hours per&#xD;
             week, or equivalent sports activities, for at least 6 months prior to enrollment.&#xD;
&#xD;
          -  Group 2: Genotype positive (G+) cardiac phenotype negative (P-) patients with variant&#xD;
             ATTR (i.e. carriers without evidence of disease)&#xD;
&#xD;
          -  Group 3: Patients with ATTR CA who have not been on a stabilizer (tafamidis) within&#xD;
             the last 14 days prior to enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Taking diflunisal or daily non-steroidal anti-inflammatory drugs (NSAIDs) use within 2&#xD;
        weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmad Masri, MD</last_name>
      <phone>503-494-8582</phone>
      <email>masria@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Ahmad Masri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Ahmad Masri</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>exercise</keyword>
  <keyword>amyloidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

